Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
PE-22-28
Also known as: Spadin analog, PE 22-28
PE-22-28 is a synthetic heptapeptide derived from the propeptide of sortillin (spadin). It was developed as an optimized analog of spadin with improved stability and potency as a TREK-1 potassium channel blocker. Animal studies show rapid-onset antidepressant-like effects comparable to ketamine. No human clinical trials have been conducted, and it remains a research compound.
Risk Level
High RiskDifficulty
Advanced| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Selectively blocks TREK-1 (TWIK-related potassium channel 1), a two-pore-domain potassium channel involved in neuronal excitability. TREK-1 knockout mice display a depression-resistant phenotype. Blocking TREK-1 increases serotonergic neurotransmission and promotes BDNF-dependent neuroplasticity, producing antidepressant effects within days rather than weeks.
Dosing Research
No human dosing established. Underground protocols report intranasal administration at 100-500 mcg/day or subcutaneous injection at similar doses. Animal studies used intravenous and intraperitoneal routes at 0.1-1 mg/kg. Dosing is highly experimental.
Side Effects & Risks
No human safety data. Theoretical risks include seizures (TREK-1 has anticonvulsant roles), cardiac effects (TREK-1 is expressed in cardiac tissue), and unknown CNS effects from modulating neuronal excitability. The lack of any human pharmacological data makes this a high-risk compound.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.